BofA analyst Tazeen Ahmad raised the firm’s price target on Ascendis Pharma to $124 from $115 and keeps a Buy rating on the shares after the European Commission granted full marketing authorization to Yorvipath. The firm said the approval was in line with its expectations following the positive CHMP opinion announced in September. In future updates, BofA looks for color on pricing and reimbursement discussions, expectations for initial Germany penetration, and guidance on other EU launches anticipated in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma announces EC approval of YORVIPATH
- Citi opens ‘upside Catalyst Watch’ on Ascendis into FDA feedback
- Ascendis Pharma resubmits NDA for TransCon PTH to U.S. FDA
- Ascendis Pharma price target raised to $137 from $134 at Wells Fargo
- Ascendis Pharma Reports Third Quarter 2023 Financial Results